Abstract
Aspergillus fumigatus causes disease in birds. Our objectives were to determine pharmacokinetic parameters and evaluate efficacy of voriconazole (VCZ) in a novel experimental quail model. After a single oral VCZ dose of 20 or 40 mg/kg, plasma concentrations peaked 2 h postdose (5.8 and 6.9 μg/ml) and remained above 0.5 μg/ml for 4 and 12 h postdose, respectively. For the efficacy study, ten-day-old Japanese quail (n 60) were infected intratracheally with A. fumigatus conidia. Daily oral VCZ at 20 or 40 mg/kg was initiated 24 h postinfection (PI); infected diluent-treated birds were given de-ionized water orally. Preassigned birds were euthanized on days 5 or 10 PI. VCZ at 40 mg/kg prolonged survival compared to 20 mg/kg or diluent-treatment (P < 0.05) and lungs from birds given VCZ at 40 mg/kg had fewer colony forming units (CFU) than diluent-treated (P =0.03). At day 10 PI, birds treated with VCZ at 20 mg/kg had significantly fewer fungi in the lungs as demonstrated by methenamine silver stain (P =0.017) or immunohistochemistry, as compared to diluent-treated (P =0.034). Histopathologically, VCZ-treated birds did not have necrotic lesions and showed a trend toward fewer with acute inflammatory changes. VCZ at 40 mg/kg was efficacious in quail with experimental pulmonary aspergillosis.
Original language | English (US) |
---|---|
Pages (from-to) | 234-244 |
Number of pages | 11 |
Journal | Medical Mycology |
Volume | 48 |
Issue number | 2 |
DOIs | |
State | Published - 2010 |
Keywords
- Antifungal
- Aspergillosis
- Avian
- Fungal infection
- Voriconazole
ASJC Scopus subject areas
- veterinary(all)
- Infectious Diseases